What is "inotuzumab ozogamicin"

n. A humanized monoclonal antibody for the treatment of cancers.

Inotuzumab ozogamicin (CMC-544) is an antibody-drug conjugate for the treatment of cancers. It consists of the humanized monoclonal antibody inotuzumab (for CD22), linked to a cytotoxic agent from the class of calicheamicins (which is reflected by ' ozogamicin' in the drug's name).

This drug is being developed by Pfizer and UCB.

It has undergone numerous clinical trials, including two phase II trials for Non-Hodgkin lymphoma (NHL).

A Phase III trial in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who were not candidates for intensive high-dose chemotherapy was terminated for futility.

ten clinical trials were active (including one phase III for Acute Lymphoblastic Leukemia (ALL)), six still recruiting.